Alogliptin (NESINA), a dipeptidyl peptidase IV (DPP-4) inhibitor, was approved by the FDA on January 25, 2013 to improve blood sugar control in adults with type 2 diabetes. This drug had been ...
For patients with heart failure (HF), a greater focus on medication management may be needed in order to mitigate HF exacerbations caused by certain ...